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Summary
S-Adenosylhomocysteine (AdoHcy) hydrolase deficiency has been proven in a human only once, in
a recently described Croatian boy. Here we report the clinical course and biochemical abnormalities
of the younger brother of this proband. This younger brother has the same two mutations in the gene
encoding AdoHcy hydrolase, and has been monitored since birth. We report, as well, outcomes during
therapy for both patients. The information obtained suggests that the disease starts in utero and is
characterized primarily by neuromuscular symptomatology (hypotonia, sluggishness, psychomotor
delay, absent tendon reflexes, delayed myelination). The laboratory abnormalities are markedly
increased creatine kinase and elevated aminotransferases, as well as specific amino acid aberrations
that pinpoint the aetiology. The latter include, most importantly, markedly elevated plasma AdoHcy.
Plasma S-adenosylmethionine (AdoMet) is also elevated, as is methionine (although the
hypermethioninaemia may be absent or nonsignificant in the first weeks of life). The disease seems
to be at least to some extent treatable, as shown by improved myelination and psychomotor
development during dietary methionine restriction and supplementation with creatine and
phosphatidylcholine.
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S-Adenosylhomocysteine (AdoHcy) hydrolase (adenosylhomocysteinase, EC 3.3.1.1) is the
enzyme that catalyses hydrolysis of AdoHcy to adenosine and homocysteine (De La Haba and
Cantoni 1959). Its deficiency (McKusick 180960) had been proven in a human only once, in
a Croatian boy we reported recently (Barić et al 2004). The index patient presented with
myopathy, characterized by hypotonia and delayed psychomotor development from birth,
abnormally slow brain myelination (noted in MRI studies of the brain at 12.7 months) and mild
hepatitis-like findings. The main biochemical abnormalities were marked increases of creatine
kinase and aminotransferases, prolonged prothrombin time, low albumin, and specific amino
acid aberrations indicative of the aetiology: hypermethioninaemia with almost normal total
plasma homocysteine and very elevated plasma AdoHcy (up to 150 × normal) and S-
Adenosylmethionine (AdoMet) (up to 30 times normal). Activity of AdoHcy hydrolase was
severely diminished: about 3% of control in liver and 9−15% of the mean controls in fibroblasts
and red blood cells. The specific metabolic defect had been identified and the patient started
on therapy by age 12.8 months. Here we report a second patient (patient 2), a brother of the
proband. Patient 2 has been monitored since birth and was started on therapy at age 3.4 months,
by which time the diagnosis of AdoHcy hydrolase deficiency had been clearly established. We
report, also, outcomes during therapy in both patients.
METHODS
Metabolite assays
Amino acids were measured by ion-exchange chromatography using a Biochrom 20 plus
analyser (Amersham Pharmacia Biotech, Little Chalfont, Buckinghamshire, UK). Plasma total
homocysteine (tHcy) was analysed using an IMX Abbott analyser (Abbott Park, Illinois, USA).
Plasma methionine and tHcy were measured also by capillary gas chromatography–mass
spectrometry, as were cystathionine, total cysteine (tCys), dimethylglycine, and sarcosine (N-
methylglycine) (Allen et al 1993; Stabler et al 1987, 1993). Plasma and cerebrospinal fluid
(CSF) AdoMet and AdoHcy (Capdevila and Wagner 1998) and plasma phosphatidylcholine,
free choline and betaine (Koc et al 2002) were assayed as previously described. Guanidino
compounds were measured by cation-exchange chromatography with post-column
derivatization (Marescau et al 1992; Schulze et al 2001). Purines and pyrimidines were
analysed using the method of Morris and Simmonds (1985).
Assays of AdoHcy hydrolase activity
Assays of red blood cell haemolysates were carried out in the direction of synthesis of AdoHcy
by a modification of the method of Hershfield and co-workers (Hershfield et al 1979), as
described previously (Barić et al 2004). During the course of the present studies we found that
there had been an error in the units in which the AdoHcy hydrolase activities in fibroblast
extracts were expressed in the former paper (Barić et al 2004). The units should correctly have
been stated as nmol/min per mg protein instead of nmol/h per mg protein. Protein
concentrations were determined by the method of Bradford (1976).
Global DNA methylation studies
Genome-wide leukocyte DNA methylation was quantitated in packed blood cells (Pogribny et
al 1999).
Gene analysis
DNA was extracted from blood samples using standard procedures (Sambrook et al 1989). A
PCR-based approach was used to amplify the coding regions of the AdoHcy hydrolase gene,
using primers derived from introns flanking all of its exons. Primers sequences were as
previously reported (Barić et al 2004). Additional primers used were: 5′-
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GGGGCATGCTGGGACTTGTA (for amplification of exon 1), 5′-
CGTCTTCTTCCCTGGCTGAA (for exon 2) and 5′-AGCGTCCCTGGTGCTTTTGA (for
exon 3). Amplified genomic DNA was either subcloned as previously described (Marchuk et
al 1991) or submitted directly to the sequencing service (MWG-Biotech, Ebersberg, Germany).
Sequencing chromatograms were analysed using the CHROMAS software (Conor McCarthy,
Southport, Australia).
MR imaging and 1H MRS studies
These studies were performed using a 2.0 T system (Gyrex Prestige, GEMS/Elscint, USA).
The younger brother's third scan (done at age 10.5 months) was performed on Symens
Symphony 1.5 T. T2-weighted imaging was used to locate the voxels for the 1H MRS studies.
The selection of voxel position in the estimated centre of the occipital subcortical white matter
was determined visually by examining the MR images in three orthogonal planes (sagittal,
coronal, and axial) to define a 1.5 × 1.5 × 1.5 cm volume of interest. Proton MR spectroscopy
was performed by using point-resolved spectroscopy (PRESS) sequence (1500/54[TR/TE])
with 100 averages.
Informed consent was obtained from the parents for all studies done in the patients.
CASE REPORT: PRETREATMENT PERIOD IN PATIENT 2, THE YOUNGER
BROTHER
Patient 2 is the brother of the proband, whose main abnormalities are described in the
introductory part. Further details have been published previously (Barić et al 2004). The parents
are healthy and unrelated. They declined prenatal diagnosis. The pregnancy and delivery were
normal, although the umbilical cord was around the neck. Birth length was 50 cm, weight 3880
g and head circumference 36 cm. Muscular hypotonia was present at birth and increased in the
following few days when the boy had moderate respiratory difficulties and superficial
breathing. Chest radiography showed left side parahilar infiltration. The symptoms resolved
following parenteral hydration, oxygen and antibiotic therapy. The boy had mild bilateral hip
dysplasia and limited leg abduction. He was referred to the Department of Pediatrics,
University Hospital Centre, Zagreb at age 15 days. At that time spontaneous mobility was
reduced. There was generalized muscular hypotonia. Tendon reflexes, Moro's reflex and
automatic walk were absent. Plantar grasp was weak. Until age 3 months 11 days, when therapy
was started, the boy was hypotonic and psychomotor development was delayed in several
respects. Head control, in particular elevation, was weak. Primitive reflexes were weak and
easily exhausted. Tendon reflexes could not be elicited. Although he started visual fixing and
smiling at about 1 month of age, the boy was sluggish and his interest in his surroundings was
generally poor. He had convergent strabismus, sometimes with rapid uncontrolled eye
movements. The dominant impression was that psychomotor delay was becoming more evident
during the last weeks of the pretreatment period. However, in his mother's opinion he has
generally fared better than his brother at corresponding ages. The boy's growth was normal.
Brain ultrasound in the neonatal period was normal. Brain MR imaging at ages 26 days and
 months showed delayed myelination and development of frontotemporal atrophy (Figures
1A and 1B). White-matter brain MR spectroscopy on both occasions revealed a small reduction
of choline and, to a lesser extent, of creatine/phosphocreatine (Cr/PCr) with approximately
equal amounts of Cr/PCr and choline, so there was only a small reduction in the choline to Cr/
PCr ratio. The amount of N-acetylaspartate was also mildly diminished.
In contrast to his brother, patient 2 has had neither clinical nor biochemical signs clearly due
to impaired liver function. Mild elevations of serum aminotransferases are considered to be
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attributable to muscle disease, although some contribution to these elevations due to liver
involvement cannot be completely excluded. His liver showed only slight hypoechogenicity
during ultrasound study. Liver biopsy was therefore not indicated. Pretreatment muscle biopsy
was considered but was not done in view of the findings in the older brother. Electrocardiogram
and heart ultrasound were normal.
Laboratory abnormalities included markedly elevated creatine kinase, ranging from 10 860 to
16 800 U/L during the first 14 days post partum, and 687 and 1163 U/L on days 47 and 92
(reference range <228; in the first days of life up to 5 to 10 times higher). Alanine
aminotransferase (ALT) was 156 and 201 U/L up to day 14 and 75 and 67 U/L on days 47 and
92 (reference range for neonates up to 54; thereafter 14−55). Aspartate aminotransferase (AST)
was 346 and 253 U/L up to day 14 and 64 and 71 U/L on days 47 and 92 (reference ranges; up
to 140 during first 5 days post partum; 35−100 for older neonates; thereafter 11−40). The only
abnormalities of blood clotting tests were transient elevation of D-dimers and diminished factor
VII concentration. Normal findings included complete blood cell count, basic urine chemistry
and sediment, acid–base balance, urinary organic acids, serum sodium, potassium, glucose,
urea, creatinine, uric acid, γ-glutamyltranspeptidase, alkaline phosphatase, lactate, and plasma
amino acids except for methionine (for methionine see Table 1 and Figure 2).
Because of markedly elevated methionine, AdoMet, and AdoHcy in plasma of patient 1 during
the initial assays (methionine at 8 months; AdoMet and AdoHcy at 11 months), assays of these
compounds were carried out in duplicate cord blood samples from patient 2. The results were
compared with the 95% confidence intervals reported previously (Guerra-Shinohara et al
2004). The methionine concentration was 35 and 35.5 μmol/L, at most very slightly elevated
(reference 95% CI: 25.4−27.3 μmol/L). AdoMet was slightly elevated at 316 and 249 nmol/L
(reference 95% CI: 164−190 nmol/L). AdoHcy was markedly elevated at 279 and 239 nmol/
L (reference 95% CI: 48−57 nmol/L). During the first 3 months post partum until dietary
methionine restriction was started at age 102 days, plasma methionine did not rise above 74
μmol/L, whereas AdoMet and, more markedly, AdoHcy were both consistently elevated
(Figure 2 and Table 1). Prior to treatment, plasma tHcy in patient 2 was within the reference
range for his age, whereas in patient 1 it had been very slightly above (Table 1) (Reddy
1997; Vilaseca et al 1997). Pretreatment values for other metabolites related to diminished
AdoHcy hydrolase activity are also shown in Table 1.
In CSF drawn at age 3.4 months, cells, protein, and lactate were normal, as was methionine:
3.5 μmol/L (control range 2.7−5.7). CSF AdoMet was at about the upper normal limit: 507
and 528 nmol/L (duplicate assay; reference range, 376 ± 122 for ages 1 month to 14 years).
CSF AdoHcy was only slightly, if at all, elevated: 16 and 41 nmol/L (duplicate assay; reference
range 12.1 ± 10.8 for ages 1 month to 14 years), perhaps reflecting the relatively low expression
of AdoHcy hydrolase in brain (see http://symatlas.gnf.org/SymAtlas/).
Patient 2 had approximately 15% of the mean control AdoHcy hydrolase activity in
haemolysates of red blood cells, very close to the value for patient 1 (17%) determined in the
same series of assays (Table 2). The latter value agrees with the previously measured activity
in patient 1 (15% of the midpoint of the control range) (Barić et al 2004).
The global leukocyte DNA methylation was investigated by the extent of incorporation of
[3H]dCTP into DNA of packed blood cells (Figure 3). In the assay, incorporation is directly
proportional to the number of nonmethylated sites in the DNA. Therefore, decreased
incorporation into the DNA as found in the patient signifies that his DNA had fewer
nonmethylated sites (i.e. it was more extensively methylated) than DNA of controls. The same
has been previously shown in his older brother (Figure 3) (Barić et al 2004).
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Sequencing of exon 4 of the AdoHcy hydrolase gene revealed the same two mutations as
previously described in the older brother (Barić et al 2004): a maternally derived codon 112
change converting TGG to the stop codon TGA (c.336G>A; p.W112X), and a paternally
derived tyrosine-to-cysteine change (c.428A>G; p.Y143C).
TREATMENT
Outcomes during treatment of patient 2
To attempt to lower the AdoHcy and AdoMet, a low-methionine diet was introduced at age
 months, providing about 15 mg methionine/kg body weight per day over the whole follow-
up period, i.e. until the age of 19 months. Methionine-free infant formula (‘X-met Analog’,
Scientific Hospital Supplies, Liverpool, UK) was added to prevent shortages of other amino
acids and provide balance of other nutrients. Phosphatidylcholine (Phosal 75 SA, Nattermann
Phospholipid GmbH, Cologne, Germany) was supplemented at a dose of 2 × 600 mg daily.
Creatine (American Muscle, Texas, USA) supplementation of 3 g/day was started one week
later. After a few weeks on this therapy, the boy gradually became more alert with obviously
improved spontaneous movements. He gained strength, although he remained hypotonic, as
shown in particular by diminished head control. At age  months, phosphatidylcholine was
increased to 3 × 600 mg daily and creatine to 4 g daily. Convergent strabismus gradually
disappeared after the sixth month of age. Rolling over started at 7 months, unsupported sitting
at about 10 months, and crawling at 11 months. At that time, speech started with two-syllable
words. At 13 months, psychological evaluation demonstrated mild delay of psychomotor
development, with a DQ of 0.79. Motor development, speech and socialization corresponded
to an age of 10 months, while oculomotor coordination was at the 12-month level. He was able
to stand and started supported walking. Muscular hypotonia remained, but was less evident.
Weak tendon reflexes could be elicited only sporadically and with difficulty.
Brain MR imaging at age  months revealed significant improvement, with almost normal
myelination for the patient's age (Figure 1C).
A biopsy of the right deltoid muscle was done at age  months. Histological examination
revealed fairly normal muscle fibres except for slightly increased variation in fibre size.
Immunohistochemically, expressions of dystrophin, merosin and alpha-sarcoglycan were
normal. Electron-microscopic examination revealed a small number of myelin figures with
different sizes and shapes and focal myofibrillar degeneration in the subsarcolemmal regions
of an occasional muscle fibre.
Therapeutic efforts have not had significant effects on routine markers of muscle involvement.
Creatine kinase ranged from 330 to 3370 U/L with a mean of 1419 ± 964 (SD; n = 11). ALT
likewise did not normalize, ranging from 27 to 245 U/L with a mean of 86 ± 58 (SD; n = 11).
While dietary methionine restriction kept plasma methionine low, between 2.9 and 8.9 μmol/
L, the other essential amino acids remained normal, and plasma proteins and albumin were
close to the lower limit. Plasma AdoMet decreased to the range 41−239 nmol/L (Figure 2) with
a mean of 114 nmol/L (Table 1). Plasma AdoHcy dropped to the range 16−144 nmol/L (Figure
2) with a mean of 56 nmol/L (Table 1). Values for other relevant metabolites during treatment
are summarized in Table 1. In brief, plasma tHcy decreased to a low mean value of 3.1 μmol/
L; cystathionine decreased but has always been within the reference range; plasma tCys was
usually slightly low. Sarcosine and dimethylglycine were elevated, attributable at least in part
to the administration of choline (as phosphatidylcholine). Four days after introduction of the
low-methionine diet, plasma phosphatidylcholine was 1035 μmol/L, choline 13.1 μmol/L and
betaine 70.9 μmol/L. Fifty-two days after the start of creatine supplementation, plasma
guanidinoacetate was 2.14 μmol/L and creatine was 236 μmol/L.
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Leukocyte DNA methylation did not normalize during 10 months of therapy, although there
may have been a trend towards less methylation (Figure 3).
Treatment and outcome of patient 1 (the older brother)
A methionine-restricted diet was started at age 13 months. Methionine restriction (initially 15
mg/kg per day) was reached by limitation of normal, age-appropriate food (protein).
Requirements of the other amino acids and nutrients were provided by use of a methionine-
free infant formula (initially ‘X-met Analog’, then also M-AM2 (both from Scientific Hospital
Supplies, Liverpool, UK). Supplemental phosphatidylcholine was provided, initially at age 13
months, mainly as two half egg yolks/day, then, starting at 17 months, partly as purified
phosphatidylcholine, 3 × 600 mg/day. Supplemental creatine monohydrate, 5 g daily, was
added at age 13 months. Subsequent dosage changes are presented in Figure 4.
Gradual, but constant, clinical improvement has been noted in the first few months after start
of treatment. The boy gained strength and motor ability and became alert and communicative.
He was able to walk without support at age 19 months. His muscles were apparently firmer
than before. Patellar reflexes could be elicited occasionally, although with some difficulty. At
age 2 years his DQ was 0.65, indicating mild delay. All tested functions were equally
developed. After that period, his clinical condition remained stable. At age 3years, DQ was
0.67 with motor functions and expressive speech affected more than other functions. At age 3
years 8 months, i.e. 4 months before the end of the period covered in this report, his height was
101 cm (25th to 50th centile), weight 18 kg (75th to 90th centile) and head circumference 49
cm (3rd to 10th centile).
Creatine kinase remained elevated: pretreatment mean, 2690 ± 841 U/L (SD; n = 7); post-
treatment mean, 4142 ± 2054 U/L (SD; n = 40). For ALT the mean pretreatment value was
716 ± 491 U/L (SD; n = 7). During treatment these values tended initially to decrease, but
afterwards were relatively stable so that the overall mean became 210 ± 69 U/L (SD; n = 40).
Serum albumin during treatment was mostly in the lower normal range. The prothrombin time
shortened following treatment. However, it was still frequently above the normal limit, but was
responsive to vitamin K. Other coagulation changes included undetectable to low factor VII;
low antithrombin, antithrombin antigen, protein S and plasminogen; low to normal fibrinogen,
factor II, and factor X; high factor V and D-dimers.
With methionine restriction the plasma concentrations of AdoHcy, AdoMet and methionine
decreased markedly, but they varied considerably (Figure 4 and Table 1). Methionine was
usually low or within the control range, but AdoHcy and AdoMet usually remained elevated
with abnormally low AdoMet/AdoHcy ratios. tHcy became low and cystathionine decreased
to values within the control range. tCys was slightly low and was not significantly raised by
supplementation with N-acetylcysteine. Despite phosphatidylcholine supplementation, the
mean plasma level of this compound remained somewhat low, while choline increased and
became virtually normal. During treatment, betaine, dimethylglycine and sarcosine were
elevated (Table 1). Three weeks after the start of the low-methionine diet and 1 week after start
of creatine supplementation, plasma guanidinoacetate was 2.3 μmol/L (reference range 0.20
−1.64) and plasma creatine 1419 μmol/L (reference range 50−124). At the same time, in CSF
guanidinoacetate was 2.5 μmol/L (reference range 0.015−0.10) and creatine 99 μmol/L
(reference range 35−90). Urine guanidinoacetate and creatine were normal.
DNA methylation did not normalize after treatment for as long as 31 months, although (as in
patient 2) there may have been a trend towards decreased methylation (Figure 3). Brain MR
imaging was repeated at age 20 months and revealed striking improvement (Figure 5).
Although an increase in myelination normally occurs over the age span in question, the patient's
myelination went from markedly decreased for his age at 13 months to nearly normal for his
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age at 20 months. On brain proton MR spectroscopy the unassigned inverted peak near 3.78
ppm had disappeared (Figure 6).
At age 31 months, to determine the relevance of the time of sampling for measurements of
methionine, AdoMet and AdoHcy in relation to meals, we analysed the profiles of these
metabolites following either a meal with a methionine content average for the low-methionine
diet, or a methionine-rich meal taken ad libitum.Following the meal usual for the low-
methionine diet, plasma methionines remained unchanged (4 μmol/L) before and 60 and 120
min after the meal. Plasma AdoMet was 267, 198 and 157 nmol/L, respectively; plasma
AdoHcy was 600, 362 and 372 nmol/L, respectively. At the same times AdoMet/AdoHcy ratios
were 0.45, 0.55 and 0.42, respectively. Following the methionine-rich meal, methionine
increased 32, 52 and 56 μmol/L (before and 60 and 120 min after the meal). Plasma AdoMet
was 1182, 2659 and 1396 nmol/L, respectively; plasma AdoHcy was 1134, 2788 and 1699
nmol/L, respectively. At the same times, AdoMet/AdoHcy ratios were 1.04, 0.95 and 0.82,
respectively. These profiles suggest that when the patient is on a low-methionine diet with
methionine intake evenly distributed during the day, the time of sampling is not important for
assessing methionine-related metabolites. However, a single methionine-rich meal can
significantly increase AdoHcy and AdoMet, pointing to the importance of strict compliance
with methionine restriction in order to keep AdoHcy at desired low levels.
DISCUSSION
The birth of a younger brother of the first individual proven to have AdoHcy hydrolase
deficiency (Barić et al 2004) provided an opportunity to carefully follow from birth a child at
risk for this condition. Indeed, it was soon shown that this younger brother is a compound
heterozygote for the same two inactivating mutations in the gene encoding AdoHcy hydrolase
that had been found in the index patient. During the ensuing observations, both similarities and
differences between the two brothers have become evident.
Similarites between patients 1 and 2
Probable congenital myopathy due to AdoHcy hydrolase deficiency—Patient 2
manifested signs of myopathy from birth: hypotonia, sluggishness, weak or absent primitive
reflexes, and absent tendon reflexes. He had slow psychomotor development, continuously
high CK and elevated cord blood AdoMet and AdoHcy. Although for patient 1 the disease was
not closely monitored during the first months of life, it was reported that his psychomotor
development was slow from the beginning, suggesting prenatal onset in this child too. In
utero lethality of mice with a deletion that includes the AdoHcy gene is in accord with this
impression (Miller et al 1994). Together, these findings suggest that myopathy might be a
characteristic, probably congenital finding in AdoHcy hydrolase deficiency. Muscle histology
changes were unspecific, similar in both brothers but less expressed in the younger one. It is
still unclear how AdoHcy hydrolase deficiency affects muscle. Choline depletion may lead to
muscle disease (da Costa et al 2002), but the persistent elevation of creatine kinase despite
phosphatidylcholine (and creatine) supplementation suggests that lack of these compounds is
not the sole cause of adverse muscle effects in the present patients.
Disturbed myelination—This effect also seems to occur early. One of the possible causes
might be inhibition of myelin basic protein–arginine N-methyltransferase (Kim et al 1997),
resulting in abnormal methylation of myelin basic protein, an important constituent of myelin.
It has been shown that 100-fold elevation of AdoHcy decreases the activity of this
methyltransferase by about 90% (Ghosh et al 1988). Improvement following the decrease of
AdoHcy during the methionine-restricted diet is consistent with this hypothesis.
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Metabolic abnormalities and changes during therapy (Table 1)—The major
metabolic abnormalities present before treatment in both brothers were marked elevations of
plasma AdoHcy, AdoMet and methionine. As discussed (Barić et al 2004), these rises are
attributed, respectively, to decreased activity of AdoHcy hydrolase, generalized inhibition of
multiple AdoMet-dependent transmethylation reactions by AdoHcy, and downregulation of
the flux from methionine into AdoMet when AdoMet is greatly increased. Dietary methionine
restriction led to marked decreases in the plasma concentrations of these metabolites in both
boys. Both boys also had slightly elevated plasma cystathionine concentrations. Diversion of
any available homocysteine towards cystathionine synthesis due to stimulation of CBS activity
by AdoMet (Finkelstein et al 1975; Kluijtmans et al 1996; Oliveriusova et al 2002) and by
AdoHcy (Finkelstein et al 1974) may have contributed. A likely additional cause was
methionine inhibition of cystathionine γ-lyase, the enzyme that catabolizes cystathio-nine
(Stabler et al 2002). Each brother also had elevated plasma sarcosine concentrations, probably
due to increased flux through glycine N-methyltransferase. The catalytic rate of this enzyme
is enhanced by AdoMet and the activity is relatively resistant to inhibition by AdoHcy (Mudd
et al 2001). Inhibition of betaine-homocysteine methyltransferase by AdoHcy (Finkelstein et
al 1974) and methionine (Allen et al 1993) may have contributed to the pretreatment elevation
of betaine in patient 1, but the elevations of DMG in both brothers are unexplained. During
treatment, phosphatidylcholine supplementation contributes to elevations of these compounds
and of sarcosine.
DNA methylation—Before treatment, the extent of genome-wide methylation of leukocyte
DNA appeared to be increased in both brothers (Figure 3), although accurate assessment of
the extent of this phenomenon at each time-point studied is limited by the fact that the extent
of global leukocyte DNA methylation has, to our knowledge, never been carefully documented
as infants pass through the first year or two of postnatal life. Despite this limitation, the present
data provide no indication of decreased methylation of leukocyte DNA such as might have
been expected on the basis of published evidence that AdoHcy inhibition of DNA
methyltransferases leads to DNA hypomethylation (Caudill et al 2001;Yi et al 2000). However,
variation between tissues in the extents of DNA hypomethylation due to elevated AdoHcy have
led to the suggestion that regulation of DNA methylation is a complex phenomenon with tissue-
specific differences (Choumenkovitch et al 2002). Although it is firmly established that
differential methylation states exist in the human genome, the mechanisms underlying these
differences remain uncertain (Jones 2003;Reik et al 2001;Ulrey et al 2005). If AdoHcy is
elevated in AdoHcy hydrolase-deficient patients during early gestation, as it was found to be
in the cord blood of patient 2, the complex reprogramming of DNA methylation that occurs
during embryonic development (Reik et al 2001) might be affected. A situation with certain
similarities to that found in the present patients has been described by Yung and colleagues
(Yung et al 2001). These authors found, surprisingly, that with age both lymphocyte and brain
DNA became more methylated in mice heterozygous for a null mutation in DNA
methyltransferase 1 (Dnmt1) than did the DNA of control mice. They suggest that there might
be a compensatory mechanism to overcome a tendency to decreased Dnmt1 activity, and
discuss a number of effects that might account for the observed increased methylation. The
apparently excessive methylation of DNA persisted in patients 1 and 2 during dietary
methionine restriction monitored for periods of as long as 34 and 10 months, respectively,
although for both there appears to have been a tendency towards a lesser degree of increased
methylation (Figure 3). Such persistence may not be unexpected because altered DNA
methylation patterns often behave as heritable changes, producing important effects that
include gene silencing and increased rates of somatic mutation (Robertson and Jones 2000).
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Differences between patients 1 and 2
Patient 2 has less severe myopathy, attained developmental milestones earlier and had less
marked histological changes in muscle than did patient 1, and had neither manifest liver disease
nor clotting disturbance. Both before and during treatment, his concentrations of plasma
AdoHcy, AdoMet and methionine were not as high as in patient 1 (Figures 2 and 4). Although
these lines of evidence may suggest that patient 2 is initially more mildly affected than is his
older brother, this conclusion is equivocal for several reasons: treatment for patient 1 started
at age 12.8 months, whereas that for patient 2 started at age 3.4 months; there were differences
in the ages (and corresponding body protein synthesis rates) at which metabolite measurements
were made; and there were differences in dietary methionine intakes in the period just before
the diagnoses were made (patient 2 was breast-fed; patient 1 was taking mixed infant food).
Comparison of AdoHcy hydrolase activities in RBC haemolysates from patients 1 and 2
To explore the possibility that, although the brothers have the same AdoHcy hydrolase
mutations, an additional factor (or factors) might make the enzyme deficiency less severe in
patient 2, AdoHcy hydrolase activities were compared in simultaneous assays of RBC
haemolysates prepared from cells collected at the same time and stored frozen relatively-briefly
for the same period (Table 2). No significant difference in the residual activities of patients 1
and 2 were observed. In the same assays were included four control haemolysates obtained
from children spanning the ages of patients 1 and 2. There was no indication of age-dependent
changes in these control AdoHcy hydrolase activities that might confound comparison of the
activity in patient 1 with that in patient 2. Of course these results do not rule out a difference
between patients 1 and 2 in activity in liver or other organ(s) more important than red cells in
overall AdoHcy metabolism. Since there is only a single functional human AdoHcy hydrolase
gene, and the patients each inherited the same pair of alleles, it seems unlikely that any clinical
differences between them are due to variations in this gene.
Treatment efficacy
Given that mammals possess at least 39 AdoMet-dependent methyltransferases, and that most,
if not all, of these are inhibited by AdoHcy (Clark and Banfield 2001), the pathophysiology of
AdoHcy hydrolase deficiency is likely to be very complex (see Barić et al (2004) for more
extensive discussion of this point). The treatment regimen used for both patients had as its chief
aims (a) reduction of the pathological accumulation of AdoHcy which, in turn, might alleviate
AdoHcy inhibition of AdoMet-dependent methyltransferases; and (b) replenishment of
creatine and phosphatidylcholine, two quantitatively dominant products of AdoMet-utilizing
methyltransferases (Mudd and Poole 1975; Brosnan et al 2004) that might play roles in brain
and muscle structure and function and that, furthermore, could safely be administered orally.
During methionine restriction, plasma AdoHcy concentrations did indeed decrease markedly.
Indication that inhibition of methyltransferases was to some extent relieved is provided by the
decreases that occurred in AdoMet concentrations, although low methionine concentrations
probably also contributed to this decrease in AdoMet. At least in patient 1, both AdoHcy and
AdoMet concentrations fluctuated widely during methionine restriction, and both these
compounds usually remained far above normal. Variations in plasma methionine suggest there
may have been fluctuations in dietary compliance, so that changes in methionine intake may
have played a role in the variation and persistence of the AdoHcy and AdoMet elevations.
Encouraging clinical changes following initiation of therapy were the altered behaviours
(disappearance of sluggishness, acceleration of psychomotor development) and the significant
improvements of brain myelination that occurred in both brothers. These changes were more
evident in the more severely affected older brother. The liver function of the older brother,
judged by albumin and fibrinogen concentrations, ALT, and to some extent by prothrombin
time, seemed to improve during treatment, although this conclusion remains tentative. It seems
Barić et al. Page 9













reasonable to conclude provisionally that the treatment regimen utilized had some beneficial
effect on the clinical course of the disease.
Detection of AdoHcy hydrolase deficiency
If AdoHcy hydrolase deficiency is really amenable to treatment, an important issue would be
early recognition. However, for patient 1 blood methionine was shown by retrospective
analysis of the newborn screening blood spot card to be below the cut-off value in use at the
time by the relevant screening programme; and for patient 2 during the newborn period plasma
methionine was often borderline or only slightly elevated (Table 1 and Figure 2), below the
cut-off values of at least some current screening programmes. These observations suggest that
screening based on detection of marked hypermethioninaemia during the newborn or early
neonatal periods may fail to detect at least some cases. Assay of plasma AdoHcy might offer
a better chance of success.
Possible additional cases of AdoHcy deficiency
In an effort to better characterize AdoHcy hydrolase deficiency, we have tried to investigate
additional patients for whom there were some grounds for supposing they might have this
abnormality:
a. The three nonmyopathic patient siblings described by Labrune (Labrune 1990), and
thought by those authors possibly to be affected by AdoHcy hydrolase deficiency:
Comparison of DNA samples from the parents of these individuals with those for the
AdoHcy hydrolase gene sequence listed in public databases (accession no.
AL356299) showed no aberrations in splice sites or in the coding regions of the
parental AdoHcy genes, results that provide no indication that these siblings were
AdoHcy hydrolase deficient.
b. The girl, age  years, described by Gaull and co-workers with elevation of plasma
methionine, but not of tHcy, and above normal activity of liver methionine
adenosyltransferase activity (Gaull et al 1981): This girl was similar to patients 1 and
2 in regard to having myopathy, muscle histology similar to theirs, and markedly
elevated creatine kinase. As yet, it has not been possible to carry out further studies
of this family.
c. A male infant with unexplained hypermethioninaemia and myopathy, mentioned very
briefly in the paper by Gaull and co-workers as a personal communication (1980)
from Dr Neil Buist (Gaull et al 1981): This individual, now aged 26 years, has very
recently been reinvestigated and shown to have AdoHcy hydrolase deficiency (N.
Buist, S. Stabler, O. Vugrek, C. Wagner, S.H. Mudd, unpublished observations). It is
hoped that studies of this men, now underway, will provide further information about
the clinical course and the metabolic abnormalities associated with this recently
recognized condition.
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Brain MRI changes in patient 2. (A) Brain MRI (axial T2) at age 26 days showing diffuse
hyperintensity of white matter corresponding to unmyelinated axons. This pattern, with an
almost unmyelinated posterior part of internal capsule, would be characteristic for a fetus in
the last two weeks of pregnancy or for a newborn in the first days of life. (B) Approximately
the same slice at age 3.5 months showed almost no progress in myelination in comparison to
the previous examination. In addition, enlargement of subarachnoidal spaces, in particular
around frontal and temporal cortex, pointed to mild to moderate brain atrophy. (C) Brain MRI
at 10.5 months, about 7 months after start of therapy, revealed a myelination pattern close to
the normal age-related pattern (only some intragyral fibers are unmyelinated), pointing to
significant acceleration of myelination following therapy. In addition, in comparison with the
previous scan, atrophic changes are less evident
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Patient 2: plasma methionine, S-adenosylmethionine and S-adenosylhomocysteine
concentrations. Ages, in months, are shown on the horizontal axis. Concentrations are shown
on the vertical axes in logarithmic scales. The horizontal bars below the graphs show treatment
changes. Grey areas indicate time prior to treatment
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Global leukocyte DNA methylation in patients 1 and 2 before and during therapy. The extents
of incorporation of [3H]dCTP into DNA of packed blood cells at various ages are indicated by
open circles for patient 1 and solid squares for patient 2. In this assay, the greater the pre-
existing extent of methylation of the DNA, the less the incorporation of radioactivity. Thus,
the lower the value observed, the greater is the extent of methylation of the sample being
studied. The vertical arrows interrupting the points for patient 1 at age 12.8 months and those
for patient 2 at age 3.4 months indicate the start of dietary methionine restriction. Analyses
were carried out in four groups determined by the availability of samples. Group 1 contained
the sample from patient 1, age 11 months; group 2, samples from patient 1, ages 13.8−18.6
months; group 3, samples from patient 1, ages 23.8−31.6 months and patient 2, ages 0.8−3.4
months; group 4, samples from patient 1, ages 30.9−43.4 months (including repeat assays of
the samples from 30.9 and 31.6 months) and patient 2, ages 4.4−13.5 months. Because the
value for a given sample may vary slightly in serial analyses, to ensure maximum comparability
the sample from patient 1 at age 17.7 months was reassayed along with groups 3 and 4. All
values from these assays were then multiplied by a correction factor of 0.87699, calculated to
make the corrected values for the sample from patient 1 at 17.7 months the same for all groups.
Corrected values are plotted. The regression lines shown for each patient were calculated
starting with the onset of dietary methionine restriction. Controls were either infants, ages 1
or 3 months (corrected values 2263 and 2730, respectively, assayed with group 3, indicated by
×'s), or samples from older children, ages unspecified, whose samples were assayed with either
group 1 (n = 4) or group 2 (n = 3). The means for these two sets of control samples were not
statistically different, so the resulting overall control value (4125 ± 714 SD; n = 7) is shown
as the grey area between the mean + 1 SD (4839) and the mean − 1 SD (3411)
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Patient 1: plasma methionine, S-adenosylmethionine and S-adenosylhomocysteine
concentrations. The plot is drawn in same manner as that in Figure 2. Area marked by ‘a’
indicates the time span when the patient received N-acetylcysteine at a dose of 3 × 100 mg/
day
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MRI studies (axial T2) of the brain of patient 1 at ages (A) 12.7 months, before therapy, and
(B) 19.6 months, after 7 months of treatment. (A) Myelination is present only in the posterior
part of the internal capsule (arrowhead). Note the clear delineation of globi pallidi because of
unmyelinated lateral and medial lamina (double black arrow). The pattern of myelination
corresponds to an age of 2−3 months. (B) There is marked improvement, with nearly normal
myelinization for this age. There is only slight hyperintensity in peritrigonal white matter and
in cortical U-fibres in frontal and temporal gyri. Note persistent, mildly to moderately enlarged
subarachnoid spaces in the frontal and temporal lobes
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Proton MR spectra of occipital subcortical white matter of patient 1 at ages 12.7 months, (A)
before therapy, and (B) 19.6 months, after 7 months of treatment. Cr, creatine/phosphocreatine;
Cho, choline; NAA, N-acethylaspartate; Lac, lactate. The Cho/Cr ratios in both spectra are
abnormally low: 1.03. and 1.10, respectively. The normal ratio for this age span is about 1.81
± 0.16 (Filippi et al 2003). In the spectrum at 12.7 months there is an unresolved inverted peak
at 3.78 ppm (arrowhead). There is a small increase in the lactate peak in the MR spectrum at
12.7 months
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Table 1
Metabolite concentrations in plasma before and during therapy
Patient 1 Patient 2
Metabolite Before therapy During therapy Before therapy During therapy
Methionine (13−45 μmol/L) 657 ± 130 (4) 16 ± 18 (37) 44 ± 28 (6) 7 ± 2 (11)
AdoMet (93 ± 16 nmol/L) 2971 716 ± 711 (31) 817 ± 595 (5) 114 ± 71 (11)
AdoHcy (15−45 nmol/L) 5044 912 ± 903 (31) 329 ± 160 (5) 56 ± 38 (11)
tHcy (3.3−8.3 μmol/L) 14.5 3.0 ± 1 (31) 5.2 ± 0.5 (4) 3.1 ± 0.4 (11)
Cysta (44−342 nmol/L) 552 105 ± 42 (31) 398 ± 129 (4) 84 ± 17 (11)
tCys (203−369 μmol/L) 244 186 ± 24 (31) 280 ± 49 (4) 181 ± 12 (11)
Sarcosine (0.6−2.7 μmol/L) 7.5 13 ± 7 (31) 4.1 ± 1.4 (4) 5.1 ± 2.5 (11)
PtdCho (1500−2559 μmol/L) 780 1234 ± 277 (18) 1610 ± 127 (3) 1035
Choline (10.7−19.7 μmol/L) 7.8 13 ± 5 (18) 17 ± 5 (3) 13.1
Betaine (26−67 μmol/L) 211 488 ± 237 (18) 43 ± 12 (3) 70.9
DMG (1.4−5.3 μmol/L)a 11.8 32 ± 19 (31) 11.7 ± 3.2 (4) 14.7 ± 6.3 (11)
GAA (0.2−1.46 μmol/L)b 6.1, 2.1 2.3 1.4 2.14
Creatine (50−124 μmol/L) 528, 42 1419 109 236
The reference range for each metabolite is shown in parentheses. Each metabolite concentration is presented as a mean ± SD. For metabolites assayed at
more than one occasion the number of assays is indicated in parentheses. In calculating the means listed, the values for samples obtained within a few
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Table 2
AdoHcy hydrolase activities in red blood cell haemolysates
Activity Patient 1 Patient 2 Controls
nmol/h per mg protein 0.99 ± 0.33 (4) 0.90 ± 0.17 (4) 5.93 ± 1.11 (16)
% of control 17 15 100
Packed blood cells were prepared from blood samples drawn on the same day and stored frozen for no more than 25 days until assayed. When the samples
were drawn, patient 1 was aged 4 years, patient 2 was aged 18 months, and the four control subjects were aged 4 years, 36 months, 20 months and 4
months. Red blood cell haemolysates were prepared and those from each individual were assayed 4 times. Results are listed as mean ± SD (number of
assays). Means for the control subjects were, respectively, 5.60 ± 0.27 (4), 4.83 ± 0.56 (4), 7.43 ± 0.71 (4), and 5.88 ± 0.74 (4)
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